$0.00
(Market cap
$8 Mln
Revenue (TTM)
$8 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
55,366,200
5 Years Aggregate
CFO
$-289.45 Mln
EBITDA
$-299.82 Mln
Net Profit
$-317.95 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
| -93.5 | 38.6 | -89.1 | -97.9 | -76.7 | -- | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
| -74.9 | -47.3 | -49.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
0.0 | 7.9 | 8.1 | -73.1 | -703.2 | -276.4 | -- | 0.2 |
| 2.7 | 77.7 | 0.0 | -49.0 | -- | -63 | -- | 35.6 | |
| 0.5 | 1.6 | 1.7 | -34.6 | -3,246.1 | -215.6 | -- | 0.2 |
Shareholding Pattern
View DetailsAbout Omega Therapeutics Inc (OMGA)
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range... without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
President, CEO & Board Director
Mr. Mahesh Karande
-
President, CEO & Board Director
Mr. Mahesh Karande
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Omega Therapeutics Inc (OMGA)
What is the current share price of Omega Therapeutics Inc (OMGA) Today?
The share price of Omega Therapeutics Inc (OMGA) is $0.05 (NASDAQ) as of 28-Apr-2025 09:30 EDT. Omega Therapeutics Inc (OMGA) has given a return of -76.71% in the last 3 years.
What is the current PB & PE ratio of Omega Therapeutics Inc (OMGA)?
Since, TTM earnings of Omega Therapeutics Inc (OMGA) is negative, P/E ratio is not available.
The P/B ratio of Omega Therapeutics Inc (OMGA) is 0.23 times as on 28-Apr-2025, a 94 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of Omega Therapeutics Inc (OMGA)?
The 52-week high and low of Omega Therapeutics Inc (OMGA) are Rs -- and Rs -- as of 24-May-2026.
What is the market cap of Omega Therapeutics Inc (OMGA)?
Omega Therapeutics Inc (OMGA) has a market capitalisation of $ 8 Mln as on 28-Apr-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Omega Therapeutics Inc (OMGA)?
Before investing in Omega Therapeutics Inc (OMGA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.